不同降压药物对高血压患者血压变异性的影响与临床应用进展
The Impact of Different Antihypertensive Medications on Blood Pressure Variability in Hypertensive Patients and Clinical Application Progress
DOI: 10.12677/acm.2025.151078, PDF,   
作者: 李俊慧, 陈 森, 杨 佳：西安医学院研究生院，陕西 西安；郭 伟*：陕西省人民医院全科医学科，陕西 西安
关键词: 高血压；血压变异性；降压药物；Hypertension； Blood Pressure Variability； Antihypertensive Medications
摘要: 高的血压变异性(Blood Pressure Variability, BPV)已被证明是认知障碍、中风、终末期肾病、心血管事件和死亡率的独立风险因素，与血压相关的心血管风险不仅取决于平均血压水平，还取决于BPV的程度，因此临床诊疗中不仅要关注高血压患者的血压水平，更需要关注血压的波动性、昼夜节律等全天血压变化规律，不能忽略BPV对患者健康的潜在影响。本文综述了不同降压药物对高血压患者BPV的影响，并探讨其在临床应用中的进展，以期为高血压患者提供更精准的降压方案以及带来更全面高效的心血管获益。
Abstract: High blood pressure variability (BPV) has been shown to be an independent risk factor for cognitive impairment, stroke, end-stage renal disease, cardiovascular events, and mortality. The cardiovascular risk associated with blood pressure is not only dependent on the average blood pressure level but also on the degree of BPV. Therefore, in clinical practice, it is essential to focus not only on the blood pressure levels of hypertensive patients but also on blood pressure variability, circadian rhythms, and the patterns of blood pressure changes throughout the day. The potential impact of BPV on patient health should not be overlooked. This article reviews the effects of different antihypertensive medications on BPV in hypertensive patients and explores their progress in clinical applications, aiming to provide more precise antihypertensive regimens and comprehensive cardiovascular benefits for hypertensive patients.
文章引用：李俊慧, 郭伟, 陈森, 杨佳. 不同降压药物对高血压患者血压变异性的影响与临床应用进展[J]. 临床医学进展, 2025, 15(1): 565-572. https://doi.org/10.12677/acm.2025.151078

参考文献

[1] World Health Organization (2023) Global Report on Hypertension: The Race against a Silent Killer. World Health Organization.
[2] 赵冬. 中国成人高血压流行病学现状[J]. 中国心血管杂志, 2020, 25(6): 513-515.
[3] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版) [J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700.
[4] Parati, G., Ochoa, J.E., Lombardi, C. and Bilo, G. (2013) Assessment and Management of Blood-Pressure Variability. Nature Reviews Cardiology, 10, 143-155. [Google Scholar] [CrossRef] [PubMed]
[5] 李谟然, 施洁莹, 张毅. 血压测量与血压变异性评估的研究进展[J]. 中国医学前沿杂志, 2023, 15(7): 26-31.
[6] Parati, G., Bilo, G., Kollias, A., Pengo, M., Ochoa, J.E., Castiglioni, P., et al. (2023) Blood Pressure Variability: Methodological Aspects, Clinical Relevance and Practical Indications for Management—A European Society of Hypertension Position Paper. Journal of Hypertension, 41, 527-544. [Google Scholar] [CrossRef] [PubMed]
[7] 贺娟娟, 马丽. 老年高血压血压变异性的研究进展[J]. 新疆中医药, 2024, 42(2): 134-137.
[8] Sheikh, A.B., Sobotka, P.A., Garg, I., Dunn, J.P., Minhas, A.M.K., Shandhi, M.M.H., et al. (2023) Blood Pressure Variability in Clinical Practice: Past, Present and the Future. Journal of the American Heart Association, 12, e029297. [Google Scholar] [CrossRef] [PubMed]
[9] 原庆丹, 沈小梅. 血压变异指标与高血压靶器官损害风险相关性研究进展[J]. 中国全科医学, 2019, 22(22): 2766-2770.
[10] Wong, Y., Chan, Y., Hai, J.S.H., Lau, K. and Tse, H. (2021) Predictive Value of Visit-to-Visit Blood Pressure Variability for Cardiovascular Events in Patients with Coronary Artery Disease with and without Diabetes Mellitus. Cardiovascular Diabetology, 20, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[11] 翟向红. 老年原发性高血压患者动态血压变异性及其与心脏结构、泵血功能的关系[J]. 河南医学研究, 2024, 33(12): 2164-2168.
[12] Rothwell, P.M., Howard, S.C., Dolan, E., O’Brien, E., Dobson, J.E., Dahlöf, B., et al. (2010) Prognostic Significance of Visit-to-Visit Variability, Maximum Systolic Blood Pressure, and Episodic Hypertension. The Lancet, 375, 895-905. [Google Scholar] [CrossRef] [PubMed]
[13] 侯阿龙, 程文彬, 孙文静, 等. 血压变异性与认知障碍关系研究进展[J]. 中国临床医学, 2024, 31(4): 659-667.
[14] 王金鹏, 彭桂芳, 王晓丽. 老年高血压患者血压变异性与轻度认知功能障碍的关系研究[J]. 中华老年心脑血管病杂志, 2023, 25(9): 988-990.
[15] 彭科娟, 刘伟, 朱慧君. 不同降压药物联合治疗对老年高血压患者血压变异性的影响[J]. 保健医学研究与实践, 2020, 17(2): 52-56.
[16] 翟玫. 五种降压药物对原发性高血压患者血压变异性影响研究[D]: [硕士学位论文]. 北京: 北京协和医学院, 2012.
[17] Nishioka, R., Kinoshita, S., Shiibashi, M., Shimazu, T., Nakazato, Y., Yamamoto, T., et al. (2015) Evaluation of the Differences in the Effects of Antihypertensive Drugs on Blood Pressure Variability by 24-Hour Ambulatory Blood Pressure Monitoring in Chronic Cerebrovascular Disease. Journal of Stroke and Cerebrovascular Diseases, 24, 1848-1854. [Google Scholar] [CrossRef] [PubMed]
[18] Webb, A.J.S., Fischer, U. and Rothwell, P.M. (2011) Effects of Β-Blocker Selectivity on Blood Pressure Variability and Stroke. Neurology, 77, 731-737. [Google Scholar] [CrossRef] [PubMed]
[19] 陈龙飞, 吴钢, 许昌声, 等. 不同降压药对自发性高血压大鼠血压变异性及动脉粥样硬化的影响[J]. 中华高血压杂志, 2019, 27(5): 448-453.
[20] Del Mauro, J.S., Prince, P.D., Allo, M.A., Santander Plantamura, Y., Morettón, M.A., González, G.E., et al. (2020) Effects of Third-Generation Β-Blockers, Atenolol or Amlodipine on Blood Pressure Variability and Target Organ Damage in Spontaneously Hypertensive Rats. Journal of Hypertension, 38, 536-545. [Google Scholar] [CrossRef] [PubMed]
[21] Lee, J., Choi, E., Son, J., Youn, Y.J., Ahn, S., Ahn, M., et al. (2020) Comparison of Blood Pressure Variability between Losartan and Amlodipine in Essential Hypertension (COMPAS-BPV). American Journal of Hypertension, 33, 748-755. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, L., Yang, J., Li, L., Liu, D., Xie, X., Dong, P., et al. (2018) Comparison of Amlodipine versus Other Calcium Channel Blockers on Blood Pressure Variability in Hypertensive Patients in China: A Retrospective Propensity Score-Matched Analysis. Journal of Comparative Effectiveness Research, 7, 651-660. [Google Scholar] [CrossRef] [PubMed]
[23] Eguchi, K., Imaizumi, Y., Kaihara, T., Hoshide, S. and Kario, K. (2016) Comparison of Valsartan and Amlodipine on Ambulatory Blood Pressure Variability in Hypertensive Patients. Clinical and Experimental Hypertension, 38, 721-724. [Google Scholar] [CrossRef] [PubMed]
[24] Ruiz-Hurtado, G., Banegas, J.R., Sarafidis, P.A., Volpe, M., Williams, B. and Ruilope, L.M. (2017) Has the SPRINT Trial Introduced a New Blood-Pressure Goal in Hypertension? Nature Reviews Cardiology, 14, 560-565. [Google Scholar] [CrossRef] [PubMed]
[25] de Havenon, A., Petersen, N., Wolcott, Z., Goldstein, E., Delic, A., Sheibani, N., et al. (2021) Effect of Dihydropyridine Calcium Channel Blockers on Blood Pressure Variability in the SPRINT Trial: A Treatment Effects Approach. Journal of Hypertension, 40, 462-469. [Google Scholar] [CrossRef] [PubMed]
[26] 王云, 刘希波, 曹静, 等. 药物治疗盐敏感性高血压效果的系统评价和荟萃分析[J]. 中华医学杂志, 2019, 99(30): 2376-2374.
[27] Basson, M.D., Newman, W.E. and Klug, M.G. (2021) Correlations among Visit-to-Visit Blood Pressure Variability and Treatment with Antihypertensive Medication with Long-Term Adverse Outcomes in a Large Veteran Cohort. American Journal of Hypertension, 34, 1092-1099. [Google Scholar] [CrossRef] [PubMed]
[28] Chang, T.I., Reboussin, D.M., Chertow, G.M., Cheung, A.K., Cushman, W.C., Kostis, W.J., et al. (2017) Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 70, 751-758. [Google Scholar] [CrossRef] [PubMed]
[29] Kario, K., Sun, N., Chiang, F., Supasyndh, O., Baek, S.H., Inubushi-Molessa, A., et al. (2014) Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients with Hypertension. Hypertension, 63, 698-705. [Google Scholar] [CrossRef] [PubMed]
[30] Ruilope, L.M., Dukat, A., Böhm, M., Lacourcière, Y., Gong, J. and Lefkowitz, M.P. (2010) Blood-Pressure Reduction with LCZ696, a Novel Dual-Acting Inhibitor of the Angiotensin II Receptor and Neprilysin: A Randomised, Double-Blind, Placebo-Controlled, Active Comparator Study. The Lancet, 375, 1255-1266. [Google Scholar] [CrossRef] [PubMed]
[31] Huo, Y., Li, W., Webb, R., Zhao, L., Wang, Q. and Guo, W. (2018) Efficacy and Safety of Sacubitril/Valsartan Compared with Olmesartan in Asian Patients with Essential Hypertension: A Randomized, Double‐Blind, 8‐Week Study. The Journal of Clinical Hypertension, 21, 67-76. [Google Scholar] [CrossRef] [PubMed]
[32] 陈鹏. 沙库巴曲缬沙坦对高血压患者血压变异性的影响[J]. 心血管病防治知识, 2023, 13(25): 16-18.
[33] 刘云, 冯玉宝. 沙库巴曲缬沙坦治疗原发性高血压的临床效果[J]. 临床医学研究与实践, 2023, 8(15): 33-36.
[34] 严同, 钟晓卫, 傅徐泉, 等. 起始剂量达格列净单药治疗对2型糖尿病患者血压影响的荟萃分析[J]. 中华高血压杂志, 2015, 23(5): 457-464.
[35] Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. (2013) Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-Analysis. Annals of Internal Medicine, 159, 262-274. [Google Scholar] [CrossRef] [PubMed]
[36] Georgianos, P.I. and Agarwal, R. (2019) Ambulatory Blood Pressure Reduction with SGLT-2 Inhibitors: Dose-Response Meta-Analysis and Comparative Evaluation with Low-Dose Hydrochlorothiazide. Diabetes Care, 42, 693-700. [Google Scholar] [CrossRef] [PubMed]
[37] Baker, W.L., Buckley, L.F., Kelly, M.S., Bucheit, J.D., Parod, E.D., Brown, R., et al. (2017) Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association, 6, e005686. [Google Scholar] [CrossRef] [PubMed]
[38] 唐正萍, 赵志颖, 金静, 等. 缬沙坦氨氯地平片对老年高血压患者血压变异性和血管弹性功能的影响[J]. 中华高血压杂志, 2019, 27(10): 964-967.
[39] 王配斯, 王勇, 杨静. 达格列净联合沙库巴曲缬沙坦钠对慢性心力衰竭患者心功能及预后的影响[J]. 临床合理用药, 2023, 16(5): 4-8.
[40] Ma, Y. (2024) Empagliflozin Combined with Sacubitril/Valsartan in Hypertensive Patients with Heart Failure: A Retrospective Study of Efficacy and Effect on Blood Pressure Variability and Cardiac Function. American Journal of Translational Research, 16, 3036-3045. [Google Scholar] [CrossRef] [PubMed]
[41] 潘国焰, 陈金灶, 林雪萍, 等. 达格列净联合沙库巴曲缬沙坦治疗2型糖尿病合并高血压心脏病患者的疗效[J]. 中国卫生工程学, 2024, 23(5): 681-683.

为你推荐